地址：广东省广州市天河区黄埔大道西601号暨南大学成教楼七楼
邮编：510632
电话：020-85220627
邮箱：lyk070@jnu.edu.cn
一、个人经历
1．学习经历
2007/9 - 2012/12，武汉大学，生命科学学院，病毒学国家重点实验室，博士
2003/9 - 2007/7，武汉大学，生命科学学院，生命科学与技术基地班，本科
2．工作经历
2013-2019/3，华中科技大学，同济医学院附属协和医院，助理研究员
2019/3-至今，暨南大学，病原微生物研究院，副研究员
2022/10-至今，暨南大学，佛山病原微生物研究院，研究员
二、研究和学术简介
研究方向为病毒感染的炎症和免疫反应分子机制、抗病毒免疫治疗技术和活性生物材料研发等。共发表学术论文30多篇，其中一作和通讯作者论文先后在Sig Trans Targ Ther，Nat Commun, Protein Cell, J Med Virol, Cancer Res, J Biol Chem，J Immunol，J Exp Clin Canc Res, Appl Mat Today，Oncoimmunology等知名期刊上发表。论文累计被他人引用总次数1700余次，H指数为17；获得国家发明专利授权5项；主持承担各级科研项目8项，包含国家自然科学基金，广东省和广州市自然科学基金等，参与国家级科研项目5项；学术兼职包括中国医疗保健国家交流促进会并临床工程与健康产业分会，委员，湖北医学生物免疫学会并再生医学与免疫专委会，常务委员；学术杂志The Innovation青年编委；Viruses杂志客座编辑；Front Cell Infect Microbiol杂志客座编辑。承担暨南大学本科生《病原微生物学》、《毒理学基础》等课程的教学任务。
三、学术论文
[1] A programmable DNA nanodevice for colorimetric detection of DNA methyltransferase activity using functionalized hemin/G-quadruplex DNAzyme. Wenxu Yuan, Kaiting Xiao, Xingxing Liu, Yanming Lai, Fazeng Luo, Wei Xiao, Jinjun Wu, Pan Pan*, Yongkui Li*, Heng Xiao*. Analytica Chimica Acta. 2023, 1273:341559. (通讯，IF=6.2)
[2] SARS-CoV-2 N protein enhances the anti-apoptotic activity of MCL-1 to promote viral replication. Pan Pan#*, Weiwei Ge#, Zhiwei Lei#, Wei luo#, Yuqing Liu, Zhanwen Guan, Lumiao Chen, Zhenyang Yu, Miaomiao Shen, Dingwen Hu, Qi Xiang, Wenbiao Wang, Pin Wan, Mingfu Tian, Yang Yu, Zhen Luo, Xulin Chen, Heng Xiao, Qiwei Zhang, Xujing Liang, Xin Chen*, Yongkui Li*, Jianguo Wu. Signal Transduction and Targeted Therapy. 2023, 8:194. (通讯，IF=39.3)
[3] Natural Oncolysis of Enterovirus 71 in Antitumor Therapy of Colorectal Cancer. Zhihui Ruan, Jiangyang Chi, Yue Kong, Chengcheng Li, Xiaolan Ruan, Xing Zhou, Yanxi Chen, Yongkui Li*, and Zhen Luo*. Advanced Biology. 2023, 2200336. (通讯, IF = 3.7 )
[4] The roles of critical pro-inflammatory cytokines in the drive of cytokine storm during SARS-CoV-2 infection. Muhammad Suhaib Qudus, Mingfu Tian, Summan Sirajuddin, Siyu Liu, Uzair Afaq, Muneeba Wali, Jinbiao Liu, Pan Pan, Zhen Luo, Qiwei Zhang, Ge Yang*, Pin Wan*, Yongkui Li*, Jianguo Wu. Journal of Medical Virology. 2023, 95:e28751. (通讯，IF = 12.7)
[5] Inhibition of PIKFYVE kinase interferes ESCRT pathway to suppress RNA virus replication. Zhen Luo, Yicong Liang, Mingfu Tian, Rui Su, Muhammad Adnan Shereend, Jialing Yin, Zhihui Ruan, Kailang Wu, Jun Guo, Qiwei Zhang*, Yongkui Li*, and Jianguo Wu*. Journal of Medical Virology. 2023, 95(2): e28527 (通讯，IF =12.7)
[6] Innate Immunity, Inflammation, and Intervention in HBV Infection. Ge Yang#, Pin Wan#, Yaru Zhang, Qiaoru Tan, Muhammad Suhaib Qudus, Zhaoyang Yue, Wei Luo, Wen Zhang, Jianhua Ouyang, Yongkui Li*, Jianguo Wu. Viruses. 2022, 14, 2275. (通讯，IF =4.7)
[7] G-Quadruplex Linked DNA Guides Selective Transfection into Nucleolin-Overexpressing Cancer Cells. Mengxi Xiang#, Yongkui Li#, Jia Liu, Jie Shi, Yizhi Ge, Chen Peng, Yawen Bin, Zheng Wang*, Lin Wang*. Pharmaceutics, 2022, 14, 2247. (共一作，IF = 5.4)
[8] ASB17 facilitates the burst of LPS-induced inflammation through maintaining TRAF6 stability. Pin Wan#, Ge Yang#, Simeng Zhang, Yaru Zhang, Yaling Jia, Xu Che，Zhen Luo, Pan Pan, Geng Li, Xulin Chen, Qiwei Zhang, Wen Zhang, Qiuping Tan, Yongkui Li*, Jianguo Wu*. Frontiers in Cellular and Infection Microbiology, 2022, 12:759077. (共通讯，IF = 5.7)
[9] Sericin and sericin-derived peptide alleviate viral pathogenesis in mice though inhibiting lactate production and facilitating antiviral response. Yongkui Li#, Ying Huang#, Pan Pan#, Xu Che, Yaru Zhang, Yeshun Zhang, Algahtany Amal, Xin Li, Wenjing Niu, Nachuan Luo, Wen Zhang, Daolong Gao, Qiuping Tan, Qiwei Zhang, Xiwen Xing*, Zhen Luo*, and Jianguo Wu*. Applied Materials Today, 2021, 25:101256. (IF =8. 3)
[10] SARS-CoV-2 N protein promotes the NLRP3 inflammasome to induce hyperinflammation. Pan Pan#, Miaomiao Shen#, Zhenyang Yu#, Weiwei Ge, Keli Chen, Minfu Tian, Feng Xiao, Zhenwei Wang, Jun Wang, Yaling Jia, Wenbiao Wang, Pin Wan, Jing Zhang, Weijie Chen, Zhiwei Lei, Xin Chen, Zhen Luo, Qiwei Zhang, Meng Xu1, Geng Li*, Yongkui Li*, and Jianguo Wu*. Nature Communications. 2021, 12:4664 (共通讯，IF =16.6)
[11] Targeting inhibition of Foxp3 by MMP2/9 sensitive short peptide linked P60 fusion protein 6 (P60-MMPs) to enhance anti-tumor immunity. Xiuli Ding#, Chen Peng#, Yongkui Li#, Jia Liu, Yu Song, Bo Cai, Mengxi Xiang, Jian Zhang, Zheng Wang*, Lin Wang*. Macromolecular Bioscience. 2020 May 25:e2000098. (共一作，IF = 4.6)
[12] Uhrf1-Mediated Tnf-α Gene Methylation Controls Proinflammatory Macrophages in Experimental Colitis Resembling Inflammatory Bowel Disease. Qi Shanshan#, Li Yongkui#, Dai Zhen, Xiang Mengxi, Wang Guobin, Wang Lin, Wang Zheng. Journal of Immunology. 2019 Dec 1;203(11):3045-3053. (共一作，IF = 4.4)
[13] Alginate Enhances Memory Properties of Antitumor CD8+ T Cells by Promoting Cellular Antioxidation. Yongli Fan#, Yongkui Li#, Jian Zhang, Xiuli Ding, Jinyuan Cui, Guobin Wang*, Zheng Wang*, Lin Wang*. ACS Biomaterials Science & Engineering 2019 Sep; 5(9): 4717-4725 (共一作，IF = 5.8)
[14] IL-33 facilitates proliferation of colorectal cancer dependent on COX2/PGE2. Yongkui Li#, Jie Shi#, Shanshan Qi, Jian Zhang, Dong Peng, Zhenzhen Chen, Guobin Wang*, Zheng Wang*, and Lin Wang*. Journal of Experimental & Clinical Cancer Research (2018) 37:196. (IF =11.3)
[15] IL33 Promotes Colon Cancer Cell Stemness via JNK Activation and Macrophage Recruitment. Min Fang#, Yongkui Li#, Kai Huang#, Shanshan Qi, Jian Zhang,Witold Zgodzinski, Marek Majewski, Grzegorz Wallner, Stanislaw Gozdz, Pawel Macek, Artur Kowalik, Marcin Pasiarski, Ewelina Grywalska, Linda Vatan, Nisha Nagarsheth,Wei Li, Lili Zhao, Ilona Kryczek, Guobin Wang, Zheng Wang,Weiping Zou, and Lin Wang. Cancer Research. 2017 May 15;77(10):2735-2745. (共同一作，IF = 11.2，当期封面论文)
[16] Hydrogel dual delivered celecoxib and anti-PD-1 synergistically improve antitumor immunity. Yongkui Li#, Min Fang#, Jian Zhang, Jian Wang, Yu Song, Jie Shi, Wei Li, Gang Wu, Jinghua Ren, Zheng Wang, Weiping Zou, and Lin Wang. Oncoimmunology. 2015 Aug 12;5(2):e1074374. (IF = 7.2)
[17] Inducible IL-32 exerts extensive antiviral function via selective stimulation of IFN-lambda1. Yongkui Li#, Jiajia Xie#, Xiupeng Xu, Li Liu, Yushun Wan, Yingle Liu, Zhu Ying*. Journal of Biological Chemistry. 2013; 288(29):20927–41. (IF = 4.8)
[18] MicroRNA-548 down-regulates host antiviral response via direct targeting of IFN-lambda1. Yongkui Li, Jiajia Xie, Xiupeng Xu, Jun Wang, Fang Ao, Yushun Wan, Ying Zhu*. Protein & Cell. 2013; 4 (2): 130-41. (IF = 21.1)
[19] A vaccine delivery system promotes strong immune responses against SARS-CoV-2 variants. Zhiwei Lei, Leqing Zhu, Pan Pan, Zhihui Ruan, Yu Gu, Xichun Xia, Shengli Wang, Weiwei Ge, Yangrong Yao, Fazeng Luo, Heng Xiao, Jun Guo, Qiang Ding, Zhinan Yin, Yongkui Li, Zhen Luo, Qiwei Zhang, Xin Chen, Jianguo Wu. J Med Virol. 2023; 95: e28475. (IF = 12.7)
[20] Crosstalk between macrophage-derived PGE2 and tumor UHRF1 drives hepatocellular carcinoma progression. Jian Zhang, Hongyan Zhang, Xiuli Ding, Jia Hu, Yongkui Li, Jinxiang Zhang, Hui Wang, Shanshan Qi, Aqing Xie, Jie Shi, Mengxi Xiang, Yawen Bin, Guobin Wang, Lin Wang, Zheng Wang. Theranostics, 2022, 12(8):3776. (IF=12.4)
[21] Zika virus non-structural protein 4B interacts with DHCR7 to facilitate viral infection. Weijie Chen, Yukun Li, Xiuling Yu, Zhenwei Wang, Wenbiao Wang, Menglan Rao, Yongkui Li, Zhen Luo, Qiwei Zhang, Jinbiao Liu, Jianguo Wu. Virologica Sinica, 2022 Sep 28;S1995-820X(22)00157-2. (IF=5.5)
[22] Hypoxia signaling in human health and diseases: implications and prospects for therapeutics. Zhen Luo, Mingfu Tian, Ge Yang, Qiaoru Tan, Yubing Chen, Geng Li, Qiwei Zhang, Yongkui Li, Pin Wan, Jianguo Wu. Signal Transduction and Targeted Therapy. 2022 Jul 7;7(1):218. (IF=39.3)
[23] Optimization of loop-mediated isothermal amplification (LAMP) assay for robust visualization in SARS-CoV-2 and emerging variants diagnosis. Zhen Luo, Chunhong Ye, Heng Xiao, Jialing Yin, Yicong Liang, Zhihui Ruan, Danju Luo, Daolong Gao, Qiuping Tan, Yongkui Li, Qiwei Zhang, Weiyong Liu, Jianguo Wu. Chemical Engineering Science. 2022 Apr 6; 251: 117430. (IF=4.7)
[24] Advances in the development of therapeutic strategies against COVID-19 and perspectives in the drug design for emerging SARS-CoV-2 variants. Jialing Yin, Chengcheng Li, Chunhong Ye, Zhihui Ruan, Yicong Liang, Yongkui Li, Jianguo Wu*, Zhen Luo*. Comput Struct Biotechnol J 2022; 20: 824-837. (IF=6.155)
[25] AP-1 signaling pathway promotes pro-IL-1β transcription to facilitate NLRP3 inflammasome activation upon influenza A virus infection. Pin Wan#, Simeng Zhang#, Zhihui Ruan, Xueli Liu, Ge Yang, Yaling Jia, Yongkui Li, Pan Pan, Wenbiao Wang, Geng Li, Xulin Chen, Zhixin Liu, Qiwei Zhang*, Zhen Luo*, Jianguo Wu*. Virulence. 2022, 13(1):502-513. (IF =5.2)
[26] HIF-1α promotes SARS-CoV-2 infection and aggravates inflammatory responses to COVID-19. Mingfu Tian#, Weiyong Liu#, Xiang Li#, Peiyi Zhao, Muhammad Adnan Shereen, Chengliang Zhu, Shanyu Huang, Siyu Liu, Xiao Yu, Miaomiao Yue, Pan Pan, Wenbiao Wang, Yongkui Li, Xulin Chen, Kailang Wu, Zhen Luo*, Qiwei Zhang*, Jianguo Wu*. Signal Transduction and Targeted Therapy 2021 Aug 18; 6(1):308. (IF =39.3)
[27] Sox4 represses host innate immunity to facilitate pathogen infection by hijacking the TLR signaling networks. Jian Shang, Yuan Zheng, Jiayin Mo, Wenbiao Wang, Zhen Luo, Yongkui Li, Xulin Chen, Qiwei Zhang, Kailang Wu, Weiyong Liu, Jianguo Wu*. Virulence. 2021;12(1):704-722. (IF =5.2)
[28] The TLR3/IRF1/Type III IFN Axis Facilitates Antiviral Responses against Enterovirus Infections in the Intestine. Rui Su#, Muhammad Adnan Shereen#, Xiaofeng Zeng#, Yicong Liang , Wen Li , Zhihui Ruan, Yongkui Li, Weiyong Liu, Yingle Liu, Kailang Wu, Zhen Luo*, Jianguo Wu*. mBio. 2020 Nov 17;11(6): e02540-20. (IF =6.4)
[29] Soluble interleukin-6 receptor is elevated during influenza A virus infection and mediates the IL-6 and IL-32 inflammatory cytokine burst. Jun Wang#, Qing Wang, Tao Han, Yongkui Li, Shengli Zhu, Fang Ao, Jian Feng, Mingzhen Jing, Li Wang, Linbai Ye, Ying Zhu*. Cellular & Molecular Immunology, 2015 Sep; 12(5): 633-44. (IF = 12.7)
[30] Exploring natural silk protein sericin for regenerative medicine: an injectable, photoluminescent, cell-adhesive 3D hydrogel. Zheng Wang#, Yeshun Zhang#, Jinxiang Zhang, Lei Huang, Jia Liu, Yongkui Li, Guozheng Zhang, Subhas C. Kundu, Lin Wang*. Scientific Reports. 2014; 4:7064-74. (IF = 4.6)
[31] Ischemic stroke and repair: current trends in research and tissue engineering treatments. Wang, Jian; Yang, Wen; Xie, Hongjian; Song, Yu; Li, Yongkui; Wang, Lin. Regenerative Medicine Research. 2014, Dec;2(1):No.3. (IF = 2)
[32] Epigenetic changes mediated by microRNA miR29 activate cyclooxygenase-2 and lambda-1 interferon production during viral infection. Jiali Fang#, Qian Hao, Li Liu, Yongkui Li, Jianguo Wu, Xixiang Huo, and Ying Zhu*. Journal of Virology. 2012; 86:1010-20. (IF = 5.4)
[33] High-throughput screen of protein expression levels induced by cyclooxygenase-2 during influenza a virus infection. Li Liu#, Rui Li, Ying Pan, Jing Chen, Yongkui Li, Jianguo Wu, Ying Zhu*. Clinica Chimica ACTA. 2011; 412:1081-5. (IF = 5.0)
[34] IL-32: a host proinflammatory factor against influenza viral replication is upregulated by aberrant epigenetic modifications during influenza A virus infection. Wei Li#, Wei Sun#, Li Liu, Fang Yang, Yongkui Li, Yanni Chen, Jiali Fang, Wenjing Zhang, Jianguo Wu and Ying Zhu*. Journal of Immunology. 2010; 185:5056-65. (IF =4.4)
[35] Hepatitis B virus X protein suppresses virus-triggered IRF3 activation and IFN-beta induction by disrupting the VISA-associated complex. Xianmiao Wang#, Ying Li, Aiping Mao, Chao Li, Yongkui Li and Po Tien*. Cellular & Molecular Immunology. 2010;7:341-8. (IF = 24.1)
[36] 乙型肝炎重症化进程中病毒学特点及其致病机制. 徐秀鹏，李永奎，朱应.传染病信息2011年8月30日,第24卷,第4期,页码：248-251.
四、科研项目
1. 百济神州公司-横向课题，40121219 ，不同理化特性的病毒的制备及初步纯化工艺开发，2021.10.18 -2022.3.1，24万元，主持。
2. 广州市基础研究计划-基础与应用基础研究项目，202102080419,丝胶增强细胞抗病毒天然免疫的机制及应用研究，2021.4.1-2023.3.31，5万元，主持。
3. 广东省自然科学基金-面上项目，2020A1515010369，乙肝病毒相关肝细胞癌组织微环境中NLRP3炎症小体促进HCC干细胞活性机制研究，2019.10.01- 2022.09.30, 10万元，主持。
4. 暨南大学中央高校基本科研业务费-跃升计划项目，NLRP3炎症小体激活肝癌干细胞转录因子机制研究，2020.01-2021.12, 8万元，主持。
5. 暨南大学人才引进计划，50万元，2019.03-2022.03，50万元，主持。
6. 国家自然科学基金-青年科学基金项目，81502572、白细胞介素-33促进结直肠肿瘤干细胞活性机制研究、2016.01-2018.12，18万元、已结题、主持。
7. 华中科技大学自主创新基金青年教师基金，2014QN067，白细胞介素-33对肿瘤干细胞特性的调控作用，2014/04-2015/12、2万元，已结题，主持。
8. 华中科技大学同济医学院附属协和医院，2016年度科学培育基金，02.03.207-25，3万元，已结题，主持。
9. 国家自然科学基金-青年科学基金项目，81402875，智能响应性多功能超分子阳离子基因传递系统的研究，2015.01-2017.12，23万元，参与。
10. 科技部国际合作项目，S2014ZR0340，新型智能生物支架应用于恶性肿瘤免疫治疗的合作研发，2014/01-2017/12，182万元，结题，参与。
11. 教育部科学技术研究项目, 113044A，脑卒中的组织工程修复疗法、 2014/1-2016/12，50万元，结题，参与。
12. 国家自然科学基金-青年科学基金项目，81801578，胰岛素诱导的巨噬细胞糖原代谢在肥胖引起的慢性炎症中的作用研究、2019/01/01~2021/12/30，21万元，在研，参与。
13. 国家自然科学基金-面上项目，81773263，光控释放非分泌型TNF-α的智能型巨噬细胞用于转移性结肠癌的治疗，2018/01/01~2019/12/30，25万元，结题，参与。
五、发明专利
1.《一种可介导生物大分子透皮吸收的组合剂、制备方法及应用》，国家专利授权(专利号ZL202110377048.4)，发明人：李永奎，吴建国，罗震，邢曦雯，潘攀。
2.《S63845在制备抗新冠病毒感染药物中的应用》国家专利授权(专利号ZL202110377048.4)，发明人：潘攀，申苗苗，陈俊，葛威威，李永奎。
3. 《丝胶蛋白、提取方法、作为细胞抗病毒免疫增强剂和应用》，专利号ZL202010961734.1，发明人：吴建国，李永奎，黄颖，邢曦雯，罗震，潘攀，张业顺。
4. 《一种含有胶原蛋白结合结构域的融合蛋白》，国家专利授权（专利号 ZL201610962104.X），发明人：王琳，王征，李永奎，徐妞妞，张剑
5. 《丝胶蛋白水凝的制备方法及其应用》，国家专利授权（专利号ZL201410071402.0），发明人：王琳，张业顺，黄雷，刘佳，王征，李永奎，杨文，乞超。